RVMD · Company research
Revolution Medicines, Inc. Common Stock (RVMD): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
20records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Revolution Medicine’s $39,800-Monthly Cancer Drug Puts Access In Focus — CEO Goldsmith Expects Insurers To Move ‘Swiftly’ To Provide Coverage - Stocktwits | Revolution Medicine’s $39,800-Monthly Cancer Drug Puts Access In Focus — CEO Goldsmith Expects Insurers To Move ‘Swiftly’ To Provide Coverage Stocktwits | View source ↗ | Stocktwits | Oct 17, 2026 | neutral | 0 | 0.6 |
| Revolution Medicines Stock Price Forecast. Should You Buy RVMD? - StockInvest.us | Revolution Medicines Stock Price Forecast. Should You Buy RVMD? StockInvest.us | View source ↗ | StockInvest.us | Oct 16, 2026 | neutral | 0 | 0.6 |
| What's Going On With Revolution Medicines Stock Friday? - Revolution Medicines (NASDAQ:RVMD) - Benzinga | What's Going On With Revolution Medicines Stock Friday? - Revolution Medicines (NASDAQ:RVMD) Benzinga | View source ↗ | Benzinga | Oct 16, 2026 | neutral | 0 | 0.6 |
| RVMD Initiates Coverage On by William Blair -- Rating Set to Out - GuruFocus | RVMD Initiates Coverage On by William Blair -- Rating Set to Out GuruFocus | View source ↗ | GuruFocus | Oct 16, 2026 | neutral | 0 | 0.6 |
| These 2 Stocks Have Run Circles Around the Magnificent Seven This Year, and Wall Street Says There Is More Upside Ahead | Revolution Medicines and Oruka Therapeutics have significantly outperformed the Magnificent Seven tech stocks this year, both more than doubling. Revolution Medicines gained FDA approval for Rasonque, a pancreatic cancer treatment with blockbuster potential ($20.8B peak revenue projected). Oruka Therapeutics is developing ORKA-001 for psoriasis with promising Phase 2 results and convenient once-yearly dosing. While Wall Street sees substantial upside (36% for RVMD, 95% for ORKA), both stocks carry significant risk due to clinical uncertainty and limited approval history. | View source ↗ | The Motley Fool | Oct 15, 2026 | neutral | -0.077 | 1 |
| A pancreatic cancer drug cut the risk of death by 60% versus chemotherapy in a trial. - Stock Titan | A pancreatic cancer drug cut the risk of death by 60% versus chemotherapy in a trial. Stock Titan | View source ↗ | Stock Titan | Oct 15, 2026 | neutral | 0 | 0.6 |
| Revolution Medicines (NasdaqGS:RVMD) Stock Forecast & Analyst Predictions - Simply Wall Street | Revolution Medicines (NasdaqGS:RVMD) Stock Forecast & Analyst Predictions Simply Wall Street | View source ↗ | Simply Wall Street | Oct 15, 2026 | neutral | 0 | 0.6 |
| Trading Systems Reacting to (RVMD) Volatility - Stock Traders Daily | Trading Systems Reacting to (RVMD) Volatility Stock Traders Daily | View source ↗ | Stock Traders Daily | Oct 14, 2026 | neutral | 0 | 0.6 |
| Revolution Medicines (RVMD) Stock Dips After FDA Review, But Ana - GuruFocus | Revolution Medicines (RVMD) Stock Dips After FDA Review, But Ana GuruFocus | View source ↗ | GuruFocus | Oct 8, 2026 | neutral | 0 | 0.6 |
| Revolution Medicines (RVMD) Shares Slide After FDA Review Highli - GuruFocus | Revolution Medicines (RVMD) Shares Slide After FDA Review Highli GuruFocus | View source ↗ | GuruFocus | Oct 8, 2026 | neutral | 0 | 0.6 |
| Why Revolution Medicines (RVMD) Stock Is Down Today - Quiver Quantitative | Why Revolution Medicines (RVMD) Stock Is Down Today Quiver Quantitative | View source ↗ | Quiver Quantitative | Oct 6, 2026 | neutral | 0 | 0.6 |
| About 3% of U.S. patients with metastatic pancreatic cancer survive five years. A drug pair starts testing in patients. - Stock Titan | About 3% of U.S. patients with metastatic pancreatic cancer survive five years. A drug pair starts testing in patients. Stock Titan | View source ↗ | Stock Titan | Oct 5, 2026 | neutral | 0 | 0.6 |
| Revolution Medicines (RVMD) Stock Looks Overvalued Even After Its Drug Approval - Yahoo Finance | Revolution Medicines (RVMD) Stock Looks Overvalued Even After Its Drug Approval Yahoo Finance | View source ↗ | Yahoo Finance | Sep 5, 2026 | neutral | 0 | 0.6 |
| Revolution Medicines (NASDAQ: RVMD) trust moves to sell 73,090 shares - Stock Titan | Revolution Medicines (NASDAQ: RVMD) trust moves to sell 73,090 shares Stock Titan | View source ↗ | Stock Titan | Aug 31, 2026 | neutral | 0 | 0.6 |
| Revolution Medicines Won FDA Approval One Month After Filing. Analysts See $11.5 Billion in Peak Sales. Is the Stock Still a Buy After Skyrocketing More Than 5X? - The Motley Fool | Revolution Medicines Won FDA Approval One Month After Filing. Analysts See $11.5 Billion in Peak Sales. Is the Stock Still a Buy After Skyrocketing More Than 5X? The Motley Fool | View source ↗ | The Motley Fool | Aug 28, 2026 | neutral | 0 | 0.6 |
| Why Revolution Medicines (RVMD) Stock Is Up Today - Quiver Quantitative | Why Revolution Medicines (RVMD) Stock Is Up Today Quiver Quantitative | View source ↗ | Quiver Quantitative | Aug 17, 2026 | neutral | 0 | 0.6 |
| Revolution Medicines (RVMD) Stock Looks Rich On Fresh RAS Drug Demand - Yahoo Finance | Revolution Medicines (RVMD) Stock Looks Rich On Fresh RAS Drug Demand Yahoo Finance | View source ↗ | Yahoo Finance | Aug 12, 2026 | neutral | 0 | 0.6 |
| Revolution Medicines (RVMD) Stock Looks Strong On Returns But Expensive On Value - Simply Wall Street | Revolution Medicines (RVMD) Stock Looks Strong On Returns But Expensive On Value Simply Wall Street | View source ↗ | Simply Wall Street | Aug 12, 2026 | neutral | 0 | 0.6 |
| Revolution Medicines (RVMD) Stock Looks Fully Priced With Strong Returns But Weak Value Checks - Yahoo Finance | Revolution Medicines (RVMD) Stock Looks Fully Priced With Strong Returns But Weak Value Checks Yahoo Finance | View source ↗ | Yahoo Finance | Jul 25, 2026 | neutral | 0 | 0.6 |
| 8-Day Rally Sends Revolution Medicines Stock Up 23% - Trefis | 8-Day Rally Sends Revolution Medicines Stock Up 23% Trefis | View source ↗ | Trefis | Jun 30, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.